GUMDROP : JHMI J1159 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

Histologically confirmed CRPC; testosterone = 50 ng/dL; must be on stable hormonal therapy if not surgically castrated; NO prednisone (or equiv corticosteroids) > 20 mg/day

Link:

http://clinicaltrials.gov/ct2/show/NCT01228760

Site:

Johns Hopkins Hospital

Principal Investigator:

Mario Eisenberger, M.D.